 Acasti Pharma Inc. Acasti or the Company NASDAQ: ACST TSX-V: ACST, a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre omega-3 phospholipid for the treatment of severe hypertriglyceridemia, today announced that it submitted its briefing package on April 29, 2020 to the Food and Drug Administration FDA for review. The Company is currently awaiting comments, and expects a formal response from the FDA on or before June 30, 2020. 